Akari updates Peak Bio merger conditions, CEO compensation revised, pipeline prioritization

Akari Therapeutics Plc

Merger with Peak Bio conditions include Peak Bio net cash > -$13.5M and PIPE net proceeds ≥ $10M; expected closing Q4 2024.
Post-merger combined entity to focus on Peak Bio's ADC platform and Akari's PAS-nomacopan GA program; HSCT-TMA suspended.
Interim CEO Samir Patel's monthly $50k compensation changed from shares to NQSOs with 2x ADS multiplier.
PAS-nomacopan IND filing for geographic atrophy expected in 2025; preclinical data suggests 3-month+ intravitreal dosing.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert Bazemore

director

AKTX · Akari Therapeutics Plc

Effective: 2024-09-17
Filed: September 18, 2024, 7:59 PM ET

the appointment of Robert Bazemore to serve as a director of the Board, effective as of September 17, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Bazemore was appointed as director at Akari Therapeutics Plc.

Action: appointed
Role: director

Exact text from the filing

the appointment of Robert Bazemore to serve as a director of the Board, effective as of September 17, 2024

View on SEC.gov

Akari Therapeutics Plc filing history →

Source: SEC EDGAR

accession 0000950170-24-107824

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.